Variable domains of heavy chain-only antibodies (VHH), also known as nanobodies (Nbs),
are monomeric antigen-binding domains derived from the camelid heavy chain-only …

The increasing demand for convenient, miniaturized and multifunctional antibodies
necessitates the development of novel antigen-recognition molecules for biological and …

The infectious severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is the
causative agent for coronavirus disease 2019 (COVID-19). Globally, there have been …

In the last two years, the world encountered the SARS-CoV-2 virus, which is still dominating
the population due to the absence of a viable treatment. To eradicate the global pandemic …

The identification of a novel class of shark‐derived single domain antibodies, named
vnarbodies that show picomolar affinities binding to the receptor binding domain (RBD) of …

SARS-CoV-2 is the etiological agent of the COVID-19 pandemic. Antibody-based
therapeutics targeting the spike protein, specifically the S1 subunit or the receptor binding …

The global impact of zoonotic viral outbreaks underscores the pressing need for innovative
antiviral strategies, particularly against respiratory zoonotic RNA viruses. These viruses …

Neutralizing antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) are useful for patients' treatment of the coronavirus disease 2019 (COVID-19). We …

Abstract The evolving SARS-CoV-2 Omicron strain has repeatedly caused widespread
disease epidemics, and effective antibody drugs continue to be in short supply. Here, we …

The global challenges posed by the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) pandemic have underscored the critical importance of innovative and …